Conclusion Thus study showed that the 72 patients tended to derive sustained benefit from this course of treatment. Slow acetylators responded to phenelzine to a significantly greater degree than did fast. In fast acetylators phenelzine is no better than placebo but in slow acetylators it is better to a highly significant degree. These findings are new. They are of practical importance in that they suggest that it is possible to predict response to phenelzine. They are also of theoretical importance in that they could explain the variable results which have been achieved using this drug in the past.
(St George's Hospital Medical School, Atkinson Morley's Hospital, London SW20 ONE)
Phenelzine in Phobic States
The clinical value of monoamine oxidase inhibitors in the treatment of phobic anxiety states has been reviewed previously (Kelly 1973) , and more recently the first two double-blind controlled trials of phenelzine in this disorder have been completed.
Maudsley and St George's Trial Patients suffering from severely incapacitating agoraphobia and social phobias were treated with phenelzine or placebo in a flexible dosage regime (30-90 mg daily: mean 2.6 tablets) for two months (Tyrer et al. 1973 a, b) . The trial was organized by Tyrer (1973) who assessed the patients before treatment and one month and two months after starting phenelzine or placebo. Forty patients entered the trial and 32 completed it. The analysis was performed on 14 prospectively matched pairs of patients and 4 unmatched patients treated at the Maudsley Hospital by Dr Candy and at St George's Hospital by Dr Kelly. There was a high inter-rater reliability between the treating psychiatrists, who also assessed the patients, and Dr Tyrer (r= +0.7-0.9).
The overall improvement as assessed by phobias, other symptoms, free-floating anxiety, panic attacks and social ratings, indicated that phenelzine was superior to placebo (P<0.01). There was a decrease in the patient's main and secondary phobias rated by (1) the psychiatrist (therapist and assessor combined) and (2) the patient, but the difference between the phenelzineand placebo-treated groups failed to reach the 0.05 level of significance, except for patient assessment of secondary phobias.
Almost 70 % of patients treated with phenelzine were clinically improved after two months, and males and females improved in equal proportions.
On placebo, females suffering from agoraphobia showed a 50% improvement. None of the males on placebo improved, however, and none of the patients with social phobias, or social phobias combined with agoraphobia, improved on placebo. Follow up: All the patients who entered the trial were seen subsequently after a mean interval of 8.7 months by an independent psychiatrist (Dr D Steinberg). Initial improvement was maintained at follow up.
The Allan Memorial Institute (Montreal) Trial The second trial of phenelzine in agoraphobia and social phobias was carried out by Solyom et al. (1973) . Five groups of 10 patients were matched and randomly assigned to (a) systematic desensitization, (b) aversion relief (previously reported, Solyom et al. 1971 ), (c) flooding, (d) phenelzine 15 mg three times a day with brief psychotherapy for three months, and (e) placebo with brief psychotherapy. There were significant changes in the main phobia and social adjustment ratings for the patients treated with phenelzine, but not for the patients on placebo. The Neuroticism score (Maudsley Personality Inventory) and Fear Survey Schedule scores also fell significantly in the phenelzine-treated group, but not in the placebo group. The mean psychiatric ratings of anxiety and phobias fell significantly in the phenelzine-treated patients and the latter rating also fell significantly in the placebo group.
The percentage of improvement in the phenelzine-treated patients was found to be 80-90%, compared 40-50% of the patients on placebo.
The authors concluded that phenelzine produced the most rapid change of the treatment methods considered. Consistent inter-group differences indicated that improvement was due to phenelzine and not to brief psychotherapy. They advocated adding phenelzine to one of the behaviour therapies. Follow up: With behaviour therapy there was a 10% relapse rate, but all 6 patients who stopped phenelzine relapsed.
Possible Mode ofAction ofPhenelzine
The results of the first two double-blind controlled trials of phenelzine have shown that this monoamine oxidase inhibitor can produce clinical improvement in patients suffering from severe agoraphobia and social phobias. The effect is seen between 4 and 8 weeks and patients relapse if phenelzine is withdrawn prematurely.
It has been postulated that phenelzine acts by reducing the severity and frequency of panic attacks (Kelly et al. 1970) . Once this has happened, patients can enter previously feared situations with less apprehension until, by repeated exposure, avoidance behaviour is diminished and a phobia overcome. Giving phenelzine alone without encouraging the patient to enter phobic situations would probably be less successful.
Phobic patients may differ from normal controls biochemically, because panic attacks can be precipitated much more readily in anxious patients by intravenous sodium lactate (Pitts & McClure 1967 , Kelly et al. 1971 ). We infused 8 severely anxious patients with sodium lactate and this resulted in an anxiety (panic) attack in all of them. They were subsequently treated with phenelzine for a mean duration of 10 weeks. Five of the patients showed marked clinical improvement at the time when a second sodium lactate infusion was administered. The subjective effects produced by the second infusion were considerably reduced in comparison with the prephenelzine infusion. Two patients showed only mild clinical improvement and one patient was unimproved on phenelzine, and in these patients the effects of the second infusion were similar to the first (Kelly et al. 1971) . It thus seems likely that phenelzine only modifies 'lactate-induced' anxiety if it has produced appreciable clinical improvement prior to the infusion, and that it cannot block experimentally induced anxiety in all patients by some nonspecific biochemical mechanism.
The interesting work of Johnstone & Marsh (1973) on depressed patients may enable us to predict by a biochemical examination (rate of acetylation) which phobic patients are likely to respond to phenelzine. If it were known that only phobic patients who were 'slow acetylators' were likely to respond to phenelzine, that would be a considerable advance. At first sight this question may appear unduly provocative; monoamine-oxidase inhibitors (MAOIs) have been in clinical use for sixteen years and have always been classified as antidepressant drugs. This classification has persisted despite abundant evidence that MAOIs are ineffective in severe depressive illness (Stanley & Fleming 1962 , Medical Research Council 1965 . The current view that patients with 'neurotic' depression are best helped by these agents has more to recommend it, but as this category does not hold up as a single diagnostic entity (Pilowsky et al. 1969 , Paykel 1971 , Everitt et al. 1971 it is unjustified to assume that any treatment effective in this condition is antidepressant in mechanism. The difficulties in predicting response to MAOIs in depression are well documented (Pare et al. 1962) ; before considering other mechanisms we should seriously consider whether this is because we have committed the Procrustean error of forcing our patients into a diagnostic category that does not fit them.
The effectiveness of MAOIs in the treatment of phobic anxiety (Kelly 1973 ) is unlikely to be due to an antidepressant action. Phobic anxiety states are clinically distinct from depressive illness (Marks 1969 , Fleiss et al. 1971 , although depression as a symptom may occur in phobic disorders. Our study (Tyrer et al. 1973 ) was deliberately designed to test whether clinical factors were useful predictors of response to phenelzine in chronic agoraphobic and socially phobic patients. We used prospectively matched pairs of patients in which each patient on phenelzine was matched using double-blind procedure with one taking placebo. Provided our criteria for matching were valid, the comparison between the clinical responses of each matched pair gave us the relative contributions of specific drug effects and nonspecific factors. This procedure is the essence of the controlled clinical trial but whereas most such trials are concerned with matched groups our study allowed us to investigate individual responses. The matching criteria used were
